Phase II study of cis-dichlorodiammineplatinum(II) in childhood osteosarcoma: Children's Cancer Study Group Report.
作者信息
Baum E S, Gaynon P, Greenberg L, Krivit W, Hammond D
出版信息
Cancer Treat Rep. 1979 Sep-Oct;63(9-10):1621-7.
PMID:291484
Abstract
摘要
相似文献
1
Phase II study of cis-dichlorodiammineplatinum(II) in childhood osteosarcoma: Children's Cancer Study Group Report.顺二氯二氨铂（II）用于儿童骨肉瘤的II期研究：儿童癌症研究组报告
Cancer Treat Rep. 1979 Sep-Oct;63(9-10):1621-7.
2
cis-Dichlorodiammineplatinum(II) in childhood cancer.
Cancer Treat Rep. 1979 Sep-Oct;63(9-10):1615-20.
3
cis-Dichlorodiammineplatinum (II) in small cell anaplastic bronchogenic carcinoma: a phase II study.顺二氯二氨铂（II）治疗小细胞间变性支气管癌：一项II期研究。
Cancer Treat Rep. 1979 Apr;63(4):543-5.
4
cis-Dichlorodiammineplatinum(II) in the treatment of gynecologic malignancies: phase II trials by the Gynecologic Oncology Group.
Cancer Treat Rep. 1979 Sep-Oct;63(9-10):1549-55.
5
[Cis-dichlorodiammineplatinum in osteosarcoma. Osteosarcoma Cooperative Study Group report].
Gan To Kagaku Ryoho. 1989 Apr;16(4 Pt 1):811-7.
6
Phase II evaluation of cis-dichlorodiammineplatinum(II) in advanced malignancies of the genitourinary and gynecologic organs: a Southwest Oncology Group Study.
Cancer Treat Rep. 1979 Sep-Oct;63(9-10):1557-64.
7
cis-Dichlorodiammineplatinum (II) in advanced osteogenic sarcoma.顺式二氯二氨铂（II）用于晚期骨肉瘤
Cancer Treat Rep. 1978 Feb;62(2):239-45.
8
Phase II evaluation of cis-dichlorodiammineplatinum(II) in lymphomas: a Southwest Oncology Group Study.顺二氯二氨铂（II）治疗淋巴瘤的II期评估：西南肿瘤学组研究
Cancer Treat Rep. 1979 Sep-Oct;63(9-10):1605-8.
9
Evaluation of cis-dichlorodiammineplatinum(II) in children with advanced malignant diseases: Southwest Oncology Group Studies.顺二氯二氨铂（II）在晚期恶性疾病儿童中的评估：西南肿瘤协作组研究
Cancer Treat Rep. 1979 Sep-Oct;63(9-10):1611-4.
10
Phase II study of cisplatin in advanced osteogenic sarcoma. European Organization for Research on Treatment of Cancer Soft Tissue and Bone Sarcoma Group.
Cancer Treat Rep. 1985 Feb;69(2):211-3.
引用本文的文献
1
Adjuvant and Neoadjuvant Chemotherapy for Osteosarcoma: A Historical Perspective.骨肉瘤的辅助和新辅助化疗：历史观点。
Adv Exp Med Biol. 2020;1257:1-10. doi: 10.1007/978-3-030-43032-0_1.
2
STAT3 inhibitor, cucurbitacin I, is a novel therapeutic agent for osteosarcoma.信号转导和转录激活因子3（STAT3）抑制剂葫芦素I是一种用于治疗骨肉瘤的新型治疗药物。
Int J Oncol. 2016 Dec;49(6):2275-2284. doi: 10.3892/ijo.2016.3757. Epub 2016 Nov 3.
3
The Current and Future Therapies for Human Osteosarcoma.人类骨肉瘤的当前和未来治疗方法
Curr Cancer Ther Rev. 2013 Feb;9(1):55-77. doi: 10.2174/1573394711309010006.
4
Relevance of historical therapeutic approaches to the contemporary treatment of pediatric solid tumors.历史治疗方法与当代儿科实体瘤治疗的相关性。
Pediatr Blood Cancer. 2013 Jul;60(7):1083-94. doi: 10.1002/pbc.24487. Epub 2013 Feb 15.
5
6
Addition of pamidronate to chemotherapy for the treatment of osteosarcoma.化疗中添加帕米膦酸二钠治疗骨肉瘤。
Cancer. 2011 Apr 15;117(8):1736-44. doi: 10.1002/cncr.25744. Epub 2010 Nov 8.
7
Intolerance to cisplatin--a case report.
Arch Gynecol. 1985;236(3):183-5. doi: 10.1007/BF02133962.
8
Platinum disposition after intraarterial and intravenous infusion of cisplatin for osteosarcoma. Cooperative Osteosarcoma Study Group COSS.骨肉瘤患者经动脉和静脉输注顺铂后的铂分布。骨肉瘤协作研究组COSS。
Cancer Chemother Pharmacol. 1989;24(6):376-80. doi: 10.1007/BF00257446.
Zotero 插件